Small Molecule Inhibitors Targeting Chikungunya Virus

Abstract

Chikungunya virus (CHIKV) infection in humans is rarely fatal but is often associated with chronic joint and muscle pain. Chronic CHIKV disease is highly debilitating and is associated with viral persistence. To date, there are no approved vaccines or therapeutics to prevent or treat CHIKV infections once they are established. Current palliative treatments aim to reduce joint inflammation and pain associated with acute and chronic CHIKV disease. Development of novel

Antiviral therapeutics for chikungunya virus

“…. MADTP-314, MADTP-393, and MADTP-372 are the small molecules that hindered the capping activity of CHIKV nsP1 in cell based study by blocking its guanylyl transferase activity, hence, preventing the synthesis of capped viral mRNA [32,33]. MADTP-372 was observed to be more potent than the other two as its viral RNA reduction value is 1.…”

Chikungunya: Resurgent Arbovirus and its Impact in Brazil

“…Currently, many substances are being tested against CHIKV. Synthetic, semi-synthetic and natural products are tested in in vitro and in vivo models [9][10][11][12][13].…”

Genome-Wide Approaches to Unravel the Host Factors Involved in Chikungunya Virus Replication

“…To date, many small molecule inhibitors against CHIKV have been developed, and their anti-CHIKV activities have been validated in in vitro experiments. However, since the cellular proteins targeted by the inhibitors (such as kinases and chaperone molecules) are often involved in critical biological activities of the host, the application of candidate inhibitors to the treatment of CHIKV-infected individuals remains an obstacle ( Haese et al, 2022 ). In this respect, a comprehensive understanding of the molecular interactions between the virus and host cell should provide helpful insights into the more promising druggable target(s) for the development of anti-CHIKV agents.…”